Oncology

In areas that have a higher incidence of genetic conditions, experts across different fields have to collaborate to develop cures and therapies.

Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.

Third-year fellows from Weill Cornell Medicine offer 7 key tips for establishing a foundational understanding of the field at major oncology meetings.

Those with cancer may be able to get cellular therapies more affordably if countries and health systems adopt decentralized closed-system manufacturing.

The AFSOS-Unicancer QUALIOR study did not meet its primary end point among patients with metastatic cancer.

Pimicotinib shows promising long-term efficacy and safety for treating tenosynovial giant cell tumor, offering significant patient benefits in a recent trial.

Proactive disclosure of information by clinical social workers in oncology may help equip patients to handle difficult aspects of cancer treatment.

In lower- and middle-income countries, accessibility, cost, and talent are obstacles to broadly implementing cellular therapeutics into cancer care.

A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.

Researching the feasibility of consolidating extensive information into a unified cancer database is the “tip of the iceberg”, said Leila Tchelebi, MD.

A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.

A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.

Kelly Dyckman, MSW, LCSW, offers advice for caregivers of patients with cancer, emphasizing the need for proactive self-care and recognizing burnout.

Physical therapists may play a key role in patient care before, during, and after treatment for cancer, according to Alison Ankiewicz, DPT, PT.

Kelly Dyckman, MSW, LCSW, discusses the need for proactive, not reactive, communication about posttreatment challenges to better support cancer survivors.

Pathologists should try to educate oncologists about the sensitivity and specificity of assays to help optimize care plans, said David Rimm, MD, PhD.

In the oncology setting, having discussions about mortality and death may be daunting for patients, but is vital and inevitable.

Black patients experienced lower survival rates across cancer types and several categories of urbanicity, particularly in breast and colorectal cancers.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.

Data from the phase 3 3475A-D77 trial support the FDA approval of subcutaneous pembrolizumab across different pediatric and adult solid tumor indications.

Greater regulatory and policy clarity may better optimize clinician use of artificial intelligence in treating patients with cancer.

An independent data monitoring committee recommended the continuation of the phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in PDAC in August 2025.

Clinical benefit with the investigational agent was reported among 48% of patients with solid tumors at or above the therapeutic dose threshold.